MA55404A - Compositions anticancéreuses - Google Patents

Compositions anticancéreuses

Info

Publication number
MA55404A
MA55404A MA055404A MA55404A MA55404A MA 55404 A MA55404 A MA 55404A MA 055404 A MA055404 A MA 055404A MA 55404 A MA55404 A MA 55404A MA 55404 A MA55404 A MA 55404A
Authority
MA
Morocco
Prior art keywords
anticancer compositions
anticancer
compositions
Prior art date
Application number
MA055404A
Other languages
English (en)
Inventor
Geert Verreck
Original Assignee
Aragon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52006905&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA55404(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aragon Pharmaceuticals Inc filed Critical Aragon Pharmaceuticals Inc
Publication of MA55404A publication Critical patent/MA55404A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MA055404A 2014-12-05 2015-12-03 Compositions anticancéreuses MA55404A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14196591 2014-12-05

Publications (1)

Publication Number Publication Date
MA55404A true MA55404A (fr) 2022-02-02

Family

ID=52006905

Family Applications (2)

Application Number Title Priority Date Filing Date
MA055404A MA55404A (fr) 2014-12-05 2015-12-03 Compositions anticancéreuses
MA41108A MA41108B1 (fr) 2014-12-05 2015-12-03 Compositions anticancéreuses

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA41108A MA41108B1 (fr) 2014-12-05 2015-12-03 Compositions anticancéreuses

Country Status (31)

Country Link
US (3) US20170360707A1 (fr)
EP (2) EP3842034B1 (fr)
JP (1) JP6767368B2 (fr)
KR (1) KR102348325B1 (fr)
CN (2) CN115837010B (fr)
AR (1) AR102924A1 (fr)
AU (1) AU2015358493B2 (fr)
CA (1) CA2969661C (fr)
CL (1) CL2017001372A1 (fr)
CO (1) CO2017005573A2 (fr)
CR (1) CR20170217A (fr)
CY (1) CY1123856T1 (fr)
DK (1) DK3226842T3 (fr)
EA (1) EA035988B1 (fr)
ES (2) ES2839128T3 (fr)
HR (1) HRP20201902T1 (fr)
HU (1) HUE051888T2 (fr)
IL (1) IL252324B (fr)
LT (1) LT3226842T (fr)
MA (2) MA55404A (fr)
MD (1) MD3226842T2 (fr)
MX (1) MX384382B (fr)
NI (1) NI201700069A (fr)
PL (1) PL3226842T3 (fr)
PT (1) PT3226842T (fr)
RS (1) RS61466B1 (fr)
SG (1) SG11201704264UA (fr)
SI (1) SI3226842T1 (fr)
TW (1) TWI683662B (fr)
UA (1) UA121123C2 (fr)
WO (1) WO2016090101A1 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2836424T3 (es) 2012-09-26 2021-06-25 Aragon Pharmaceuticals Inc Antiandrógenos para tratar el cáncer de próstata no metastásico y resistente a la castración
MX381829B (es) 2014-12-05 2025-03-13 Aragon Pharmaceuticals Inc Composiciones anticancerígenas.
RS66323B1 (sr) 2014-12-05 2025-01-31 Aragon Pharmaceuticals Inc Sastavi protiv raka
UA129105C2 (uk) 2017-10-16 2025-01-15 Арагон Фармасьютикалз, Інк. Антиандрогени для лікування неметастатичного резистентного до кастрації раку передміхурової залози
EP3773509B1 (fr) * 2018-04-06 2023-11-01 Capsugel Belgium NV Procédé de séchage par pulvérisation pour des particules à faible rapport d'aspect comprenant du poly[(méthacrylate de méthyle)-co-(acide méthacrylique)]
WO2020144649A1 (fr) 2019-01-10 2020-07-16 Aragon Pharmaceuticals, Inc. Composition pharmaceutique comprenant de l'enzalutamide dispersé dans une compote de pomme
CN113365623B (zh) 2019-01-30 2025-06-24 阿拉贡药品公司 用于治疗转移性去势敏感性前列腺癌的抗雄激素
EP3918607A1 (fr) 2019-01-30 2021-12-08 Janssen Pharmaceutica NV Méthodes de traitement du cancer de la prostate sur la base de sous-types moléculaires
WO2020239478A1 (fr) 2019-05-28 2020-12-03 Pharma Mar, S.A. Trabectédine pour le traitement de sarcomes basé sur des marqueurs génomiques
JP2023500935A (ja) 2019-11-04 2023-01-11 アラゴン ファーマシューティカルズ，インコーポレイテッド 重度の肝障害を有する対象における非転移性去勢抵抗性前立腺癌の治療のためのアンドロゲン受容体阻害剤
WO2021245285A1 (fr) 2020-06-05 2021-12-09 Janssen Pharmaceutica Nv Méthodes de traitement du cancer de la prostate sur la base de sous-types moléculaires
TW202228794A (zh) 2020-09-04 2022-08-01 美商艾瑞岡醫藥公司 用於治療前列腺癌之方法
WO2022195407A1 (fr) 2021-03-19 2022-09-22 Aragon Pharmaceuticals, Inc. Méthodes de traitement du cancer de la prostate
WO2023152611A1 (fr) 2022-02-11 2023-08-17 Aragon Pharmaceuticals, Inc. Apalutamide et relugolix pour le traitement du cancer de la prostate
WO2023209555A1 (fr) 2022-04-26 2023-11-02 Aragon Pharmaceuticals, Inc. Produits médicamenteux approuvés et méthodes de traitement du cancer de la prostate
CN121038790A (zh) 2023-03-16 2025-11-28 拜耳消费者护理股份有限公司 用于治疗激素敏感性前列腺癌生化复发患者的雄激素受体拮抗剂
WO2026052846A1 (fr) 2024-09-09 2026-03-12 Synthon B.V. Formulation pharmaceutique comprenant de l'apalutamide

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002080902A1 (fr) 2001-04-02 2002-10-17 Astrazeneca Ab Composition pharmaceutique solide contenant 4-cyano-trifluoro-3-(4-fluorophenylsulfonyl)-2-hydroxy-2-methylpropiono-m-toluidiure et pvp
JPWO2003077827A1 (ja) * 2002-03-19 2005-07-14 日本新薬株式会社 医薬固体分散体の製造方法
WO2005055987A1 (fr) * 2003-12-15 2005-06-23 Council Of Scientific & Industrial Research Compositions pharmaceutiques au gout masque comportant une medicament amer et un polymere sensible au ph
EP2656842B1 (fr) * 2006-03-27 2016-08-10 The Regents of The University of California Modulateur de récepteur androgène pour le traitement du cancer de la prostate et de maladies associées au récepteur androgène
HUE037389T2 (hu) * 2010-02-16 2018-08-28 Aragon Pharmaceuticals Inc Androgén receptor modulátorok és alkalmazásaik
US10071945B2 (en) * 2011-06-15 2018-09-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Nuclear receptor modulators and their use for the treatment and prevention of cancer
WO2013152342A1 (fr) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Inhibiteur de mtor anticancéreux et combinaison anti-androgène
EP3922629A1 (fr) 2012-06-07 2021-12-15 Aragon Pharmaceuticals, Inc. Formes cristallines d'un modulateur de récepteur d'androgène
US10668156B2 (en) 2012-06-22 2020-06-02 Basf Se Active-ingredient-containing solid dispersions based on diethylaminoethyl methacrylate copolymers
EP4450130A3 (fr) * 2012-09-11 2025-01-08 Medivation Prostate Therapeutics LLC Formulations d'enzalutamide
ES2836424T3 (es) * 2012-09-26 2021-06-25 Aragon Pharmaceuticals Inc Antiandrógenos para tratar el cáncer de próstata no metastásico y resistente a la castración
CA3105575A1 (fr) * 2013-01-15 2014-07-24 Aragon Pharmaceuticals, Inc. Modulateur du recepteur des androgenes et ses utilisations
UA116004C2 (uk) * 2013-01-22 2018-01-25 Ф. Хоффманн-Ля Рош Аг Фармацевтична композиція з покращеною біодоступністю
WO2014167428A2 (fr) 2013-04-10 2014-10-16 Shilpa Medicare Limited 4-(3-(4-cyano-3-(trifluorométhyl)phényl)-5,5-diméthyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-n-méthylbenzamide amorphe
WO2015023710A1 (fr) * 2013-08-12 2015-02-19 Tokai Pharmaceuticals, Inc. Biomarqueurs pour le traitement de troubles néoplasiques à l'aide de thérapies ciblant les androgènes
EP3102183A1 (fr) * 2014-02-05 2016-12-14 LEK Pharmaceuticals d.d. Compositions pharmaceutiques solides d'antagonistes du récepteur des androgènes

Also Published As

Publication number Publication date
CA2969661A1 (fr) 2016-06-09
CA2969661C (fr) 2023-04-25
LT3226842T (lt) 2021-03-25
CL2017001372A1 (es) 2018-01-05
RS61466B1 (sr) 2021-03-31
EP3842034B1 (fr) 2025-02-12
PT3226842T (pt) 2020-12-23
CR20170217A (es) 2017-08-30
EP3226842B1 (fr) 2020-11-25
CN115837010A (zh) 2023-03-24
US20170360707A1 (en) 2017-12-21
US20240293321A1 (en) 2024-09-05
DK3226842T3 (da) 2021-01-25
ES2839128T3 (es) 2021-07-05
JP6767368B2 (ja) 2020-10-14
TWI683662B (zh) 2020-02-01
ES3021508T3 (en) 2025-05-27
CO2017005573A2 (es) 2017-09-29
EP3842034A1 (fr) 2021-06-30
SG11201704264UA (en) 2017-06-29
CN115837010B (zh) 2025-03-14
JP2017536401A (ja) 2017-12-07
AU2015358493A1 (en) 2017-06-08
PL3226842T3 (pl) 2021-07-12
AR102924A1 (es) 2017-04-05
MD3226842T2 (ro) 2021-03-31
HRP20201902T1 (hr) 2021-07-23
CY1123856T1 (el) 2022-05-27
EA035988B1 (ru) 2020-09-09
WO2016090101A1 (fr) 2016-06-09
EA201791252A1 (ru) 2017-10-31
US20220151931A1 (en) 2022-05-19
EP3226842A1 (fr) 2017-10-11
HUE051888T2 (hu) 2021-03-29
MX384382B (es) 2025-03-14
UA121123C2 (uk) 2020-04-10
IL252324B (en) 2021-10-31
CN106999430A (zh) 2017-08-01
IL252324A0 (en) 2017-07-31
AU2015358493B2 (en) 2021-05-06
SI3226842T1 (sl) 2021-04-30
KR20170086657A (ko) 2017-07-26
MX2017007201A (es) 2018-01-30
BR112017011787A2 (pt) 2017-12-26
MA41108A (fr) 2016-06-09
KR102348325B1 (ko) 2022-01-06
TW201632187A (zh) 2016-09-16
NI201700069A (es) 2017-10-31
MA41108B1 (fr) 2021-03-31

Similar Documents

Publication Publication Date Title
IL279833A (en) Anti-cancer drugs
DK3151672T3 (da) Forbedrede t-celle-sammensætninger
DK3215173T3 (da) Glycopeptidsammensætninger
DK3226842T3 (da) Anticancersammensætninger
DK3089741T3 (da) Farmaceutiske sammensætninger omfattende azd9291
DK3040326T3 (da) Haloolefin-baseret sammensætning
DK3226843T3 (da) Anticancersammensætninger
FR3024363B1 (fr) Composition thermogelifiable
DK3250182T3 (da) Dispergible sammensætninger
DK3334726T3 (da) Plinabulinsammensætninger
DK3129007T3 (da) Vaccinesammensætninger
CL2017000639A1 (es) Composición
DK3316857T3 (da) Multifasiske sammensætninger
IL253276A0 (en) Anti-cancer compounds
EP3236746C0 (fr) Composition
DK3200827T3 (da) Sammensætninger
EP3298005C0 (fr) Composés anti-cancereux
DK3217964T3 (da) Sammensætning
FR3019552B1 (fr) Composition filmogene
DK3393503T3 (da) Sammensætninger